Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Ralph Brandenberger net worth and biography

Ralph Brandenberger Biography and Net Worth

Insider of Nkarta

Dr. Brandenberger joined Nkarta in 2018 and oversees the company’s cell therapy manufacturing operations. He has broad experience in process development, technical operations and manufacturing of cellular therapeutics and biologics. He was previously at Neurona Therapeutics, where he developed the manufacturing strategy for Neurona’s novel cell therapy platform. Prior to that, Dr. Brandenberger oversaw manufacturing sciences, analytical sciences and GMP cell banking as Head of Technical Operations at Baxalta Hayward, a GMP manufacturing plant of clinical stage biologics and reagents used in commercial drug substance manufacturing. Prior to joining Baxalta, Dr. Brandenberger served as Director of Process Sciences for Cellular Therapeutics at Geron Corporation where he had responsibilities for process and technology development of Geron’s pluripotent stem cell platform.

Dr. Brandenberger received a MS and PhD in Cell Biology from the Biocenter of the University of Basel, Switzerland. He completed postdoctoral training at the Howard Hughes Medical Institute at the University of California, San Francisco.

What is Ralph Brandenberger's net worth?: The estimated net worth of Ralph Brandenberger is at least $57,096.00 as of October 6th, 2022. Dr. Brandenberger owns 7,800 shares of Nkarta stock worth more than $57,096 as of April 24th. This net worth approximation does not reflect any other investments that Dr. Brandenberger may own. Learn More about Ralph Brandenberger's net worth.
How old is Ralph Brandenberger?: Dr. Brandenberger is currently 55 years old. There are 5 older executives and no younger executives at Nkarta. The oldest executive at Nkarta is Mr. Paul J. Hastings, CEO, President & Director, who is 64 years old. Learn More on Ralph Brandenberger's age.
How do I contact Ralph Brandenberger?: The corporate mailing address for Dr. Brandenberger and other Nkarta executives is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. Nkarta can also be reached via phone at 925-407-1049 and via email at [email protected]. Learn More on Ralph Brandenberger's contact information.
Has Ralph Brandenberger been buying or selling shares of Nkarta?: Ralph Brandenberger has not been actively trading shares of Nkarta over the course of the past ninety days. Most recently, Ralph Brandenberger sold 842 shares of the business's stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $14.02, for a transaction totalling $11,804.84. Following the completion of the sale, the insider now directly owns 7,800 shares of the company's stock, valued at $109,356. Learn More on Ralph Brandenberger's trading history.
Who are Nkarta's active insiders?: Nkarta's insider roster includes Ralph Brandenberger (Insider), Paul Hastings (CEO), Nadir Mahmood (Insider), and Kanya Rajangam (Insider). Learn More on Nkarta's active insiders.
Are insiders buying or selling shares of Nkarta?: During the last year, Nkarta insiders bought shares 1 times. They purchased a total of 2,000,000 shares worth more than $20,000,000.00. During the last year, insiders at the sold shares 6 times. They sold a total of 20,866 shares worth more than $178,341.54. The most recent insider tranaction occured on March, 27th when Director Simeon George bought 2,000,000 shares worth more than $20,000,000.00. Insiders at Nkarta own 5.6% of the company. Learn More about insider trades at Nkarta.
Information on this page was last updated on 3/27/2024.

Ralph Brandenberger Insider Trading History at Nkarta

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2022	Sell	842	$14.02	$11,804.84	7,800
8/8/2022	Sell	11,593	$15.51	$179,807.43	7,800
7/25/2022	Sell	3,000	$13.41	$40,230.00	7,800
6/3/2022	Sell	4,140	$15.00	$62,100.00	5,300
12/1/2021	Sell	4,140	$15.64	$64,749.60
9/1/2021	Sell	4,140	$32.08	$132,811.20	340
6/2/2021	Sell	4,140	$24.50	$101,430.00	340

Ralph Brandenberger Buying and Selling Activity at Nkarta

Nkarta Company Overview

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Today's Range

Now: $7.32

$7.30

$7.56

50 Day Range

MA: $10.64

$7.29

$15.71

2 Week Range

Now: $7.32

$1.28

$16.24

Volume

42,105 shs

Average Volume

1,866,696 shs

Market Capitalization

$361.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Protect Your Bank Account Before It’s Too Late

From Weiss Ratings | Ad